{"entity":{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","aka":[],"tldr":"Magnetic nanoparticle hyperthermia injects iron-oxide nanoparticles into a tumour and heats them from outside with an alternating magnetic field.","summary":"NanoTherm received European approval for glioblastoma in 2010 and is used at a small number of German centres, usually with radiotherapy. A phase 2 adjuvant glioblastoma study is recruiting in Poland (NCT06271421); the US prostate focal-ablation study (NCT05010759) was terminated. Systemically delivered magnetic hyperthermia, as opposed to direct intratumoural injection, is still preclinical.","status":"phase-2","asOf":"2026-09-08","links":[{"label":"NanoTherm adjuvant GBM phase 2 (NCT06271421)","url":"https://clinicaltrials.gov/study/NCT06271421"}],"tags":["frontier"],"related":[],"cancers":["glioblastoma","prostate"],"sections":["devices","radiation"],"technologies":["hyperthermia","thermal-ablation","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-hyperthermia"],"dependsOn":[],"notes":[],"principle":"Superparamagnetic iron-oxide nanoparticles deposited in the tumour dissipate heat under an alternating magnetic field, reaching 40-45 °C and sensitising cells to radiation and chemotherapy.","strengths":["Heat is generated only where particles sit","Adds to radiotherapy without extra systemic toxicity","Approved precedent in Europe"],"limitations":["Requires direct injection and a specialised field applicator","Uneven particle distribution gives uneven heating","Very few centres; a troubled commercial history"]},"route":"/technologies/magnetic-nanoparticle-hyperthermia/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/"},{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"}],"journal":[{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/"}],"roadmap":[{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/"},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/"}]}}